Clinical Trial Update: Characterize The Modulatory Effects Of Dopamine D2/D3 Receptor Agonist And Antagonist Drugs On Compulsive Behaviors [Phase 1]

View source ↗

Summary

A completed Phase 1 study evaluating how dopamine D2/D3 receptor agonist and antagonist drugs influence compulsive behaviors in obsessive-compulsive disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obsessive-compulsive Disorder

Drugs mentioned

• Dopamine D2/D3 receptor agonist
• Dopamine D2/D3 receptor antagonist

Snippet

Sponsor: GlaxoSmithKline | Conditions: Obsessive-Compulsive Disorder | Phase 1 | Status: COMPLETED